[1] 韩冰,赵倩,海盼盼,等.卡铂腹腔化疗在晚期卵巢癌患者中的应用研究[J].中国妇产科临床杂志,2020,21(3):269-271. [2] 庞会锋,田炜,亢建康,等.含酰胺结构的大黄酸衍生物4a对卵巢癌细胞的迁移、侵袭的影响[J].中国药理学通报,2020,36(2):204-209. [3] 董飞天,李瑞宁. 甲磺酸阿帕替尼治疗晚期卵巢癌的疗效及对血清HE4、hK10、CA125水平的影响[J].医学临床研究,2022,39(7):1054-1057. [4] LHEUREUX S,BRAUNSTEIN M,OZA A M. Epithelial ovarian cancer: Evolution of management in the era of precision medicine[J].CA Cancer J Clin,2019,69(4):280-304. [5] 毛咪咪,冯峰.基于肿瘤全域表观扩散系数纹理分析预测上皮性卵巢癌复发的研究[J].中国临床医学影像杂志,2020,31(1):52-56. [6] 中国医师协会微无创医学专业委员会妇科肿瘤专业委员会(学组),中国优生科学协会生殖道疾病诊治分会,中国优生科学协会肿瘤生殖学分会. 低级别浆液性卵巢癌的专家共识(2020年版)[J].中国癌症防治杂志,2020,12(2):117-125. [7] CHANDRA A,PIUS C,NABEEL M,et al.Current status and strategies for improving therapeutic outcomes[J].Cancer Med,2019,8(16):7018-7031. [8] MURAKAMI K,KOTANI Y,SHIRO R,et al. Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts[J].Int J Clin Oncol,2020,25(1):51-58. [9] 刘娜,邢伟,褚璐璐.基于微信平台的延续性护理在卵巢癌术后患者中的应用[J].中华现代护理杂志,2021,27(13):1789-1792. [10] 韦红,史喜梅. 血清HE4、CA125联合α-羟基丁酸脱氢酶检测在卵巢癌患者中的诊断价值[J].医学临床研究,2022,39(10):1578-1580. [11] EDIRIWEERA M K,TENNEKOON K H,SAMARAKOON S R. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance[J].Semin Cancer Biol,2019,59:147-160. [12] KOTSOPOULOS J,NAROD S A. Prophylactic salpingectomy for the prevention of ovarian cancer: Who should we target[J].Int J Cancer,2020,147(5):1245-1251.
2023, Vol. 40 
